Opioid Prescribing and Dispensing: Experiences and Perspectives from a Survey of Community Pharmacists Practising in the Province of Quebec

Overview

Journal Can Pharm J (Ott)

Specialty Pharmacology

Date 2018 Dec 19

PMID 30559916

Citations 6

Authors

Pierre-Andre Dube

Julien Vachon

Caroline Sirois

Elise Roy

Affiliations

Soon will be listed here.

Abstract

Background: Canada leads in opioid prescription and consumption rates, and this has resulted in high levels of opioid-related morbidity and mortality. Pharmacists' input could contribute significantly to understanding the disadvantages of opioid prescribing and dispensing and improving the service. This study aimed to examine the experiences of community pharmacists in relation to opioid prescribing and dispensing, with a focus on optimizing collaboration and communication.

Methods: An online survey was performed among pharmacists from the province of Quebec, Canada, in 2016. Pharmacists were eligible if registered and working in community pharmacies.

Results: In all, 542 questionnaires were analyzed (participation rate of 8.1%). Pharmacotherapy-related problems were reported in at least 50% of opioid prescriptions: additional drug(s) required (reported by 30% of pharmacists), interaction(s) between opioid(s) and other drug(s) (16%), physician did not meet the general issuing standards for opioid prescriptions (26%) and patient had mild to moderate pain that was easily managed by a nonopioid analgesic (20%). Half of the patients were reported as requesting anticipated refills, possibly indicating abuse or poor pain control. Most pharmacists (89.6%) reported needing to contact physicians in 1 to 3 out of 10 opioid prescriptions, but many pharmacists (71.8%, often or very often) reported difficulties communicating with physicians.

Conclusions: Pharmacists' observations of pharmacotherapy-related problems and patients' unusual behaviours reveal a significant number of issues related to opioid prescribing and dispensing in an outpatient setting. Improved collaboration between physicians and pharmacists appears mandatory to address the issues reported in this study.

Citing Articles

A Cross-Sectional Evaluation of Opioid Dispensing Competencies in Final-Year Pharm-D Students: A Multicenter Study from Punjab, Pakistan.

Mubarak N, Rahman Rana F, Zahid T, Ijaz U, Shabbir A, Ghulam Bari A Drug Healthc Patient Saf. 2025; 16:133-144.

PMID: 39749185 PMC: 11693936. DOI: 10.2147/DHPS.S491717.

Addressing the Opioid Crisis-The Need for a Pain Management Intervention in Community Pharmacies in Canada: A Narrative Review.

Cid A, Ng A, Ip V Pharmacy (Basel). 2023; 11(2).

PMID: 37104077 PMC: 10144945. DOI: 10.3390/pharmacy11020071.

Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis.

Chang A, Chaudhry S, McCormack D, Gomes T, Shivji A, Tadrous M Can Pharm J (Ott). 2022; 155(6):326-333.

PMID: 36386607 PMC: 9647400. DOI: 10.1177/17151635221126481.

Strategies to prevent long-term opioid use following trauma: a Canadian practice survey.

Berube M, Cote C, Moore L, Turgeon A, Belzile E, Richard-Denis A Can J Anaesth. 2022; 70(1):87-99.

PMID: 36163458 PMC: 9513000. DOI: 10.1007/s12630-022-02328-8.

Pharmacists' perceptions on real-time prescription monitoring (RTPM) systems - a cross-sectional survey.

Zhang Z, Guo L, Si R, Chalmers L, Filippin P, Carpenter J Explor Res Clin Soc Pharm. 2022; 5:100122.

PMID: 35478517 PMC: 9032446. DOI: 10.1016/j.rcsop.2022.100122.

References

Hepler C . Clinical pharmacy, pharmaceutical care, and the quality of drug therapy. Pharmacotherapy. 2004; 24(11):1491-8. DOI: 10.1592/phco.24.16.1491.50950. View

Berenguer B, la Casa C, de la Matta M, Martin-Calero M . Pharmaceutical care: past, present and future. Curr Pharm Des. 2004; 10(31):3931-46. DOI: 10.2174/1381612043382521. View

Jones E, MacKinnon N, Tsuyuki R . Pharmaceutical care in community pharmacies: practice and research in Canada. Ann Pharmacother. 2005; 39(9):1527-33. DOI: 10.1345/aph.1E456. View

Koski R . Pharmacists' perceptions of controlled substance abuse in the rural upper peninsula of Michigan. J Am Pharm Assoc (2003). 2006; 46(6):751-3. DOI: 10.1331/1544-3191.46.6.751.koski. View

Pottie K, Haydt S, Farrell B, Kennie N, Sellors C, Martin C . Pharmacist's identity development within multidisciplinary primary health care teams in Ontario; qualitative results from the IMPACT project. Res Social Adm Pharm. 2009; 5(4):319-26. DOI: 10.1016/j.sapharm.2008.12.002. View

Manchikanti L, Fellows B, Ailinani H, Pampati V . Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician. 2010; 13(5):401-35. View

Wenghofer E, Wilson L, Kahan M, Sheehan C, Srivastava A, Rubin A . Survey of Ontario primary care physicians' experiences with opioid prescribing. Can Fam Physician. 2011; 57(3):324-32. PMC: 3056687. View

Allen M, MacLeod T, Zwicker B, Chiarot M, Critchley C . Interprofessional education in chronic non-cancer pain. J Interprof Care. 2011; 25(3):221-2. DOI: 10.3109/13561820.2011.552134. View

Bohnert A, Valenstein M, Bair M, Ganoczy D, McCarthy J, Ilgen M . Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011; 305(13):1315-21. DOI: 10.1001/jama.2011.370. View

10.

Kahan M, Wilson L, Wenghofer E, Srivastava A, Resnick A, Janecek E . Pharmacists' experiences with dispensing opioids: provincial survey. Can Fam Physician. 2011; 57(11):e448-54. PMC: 3215629. View

11.

Dolovich L . Ontario pharmacists practicing in family health teams and the patient-centered medical home. Ann Pharmacother. 2012; 46(4):S33-9. DOI: 10.1345/aph.1Q804. View

12.

Modarai F, Mack K, Hicks P, Benoit S, Park S, Jones C . Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend. 2013; 132(1-2):81-6. DOI: 10.1016/j.drugalcdep.2013.01.006. View

13.

Allen M, Asbridge M, Macdougall P, Furlan A, Tugalev O . Self-reported practices in opioid management of chronic noncancer pain: a survey of Canadian family physicians. Pain Res Manag. 2013; 18(4):177-84. PMC: 3812188. DOI: 10.1155/2013/528645. View

14.

Fleming M, Barner J, Brown C, Shepherd M, Strassels S, Novak S . Pharmacists' training, perceived roles, and actions associated with dispensing controlled substance prescriptions. J Am Pharm Assoc (2003). 2014; 54(3):241-50. DOI: 10.1331/JAPhA.2014.13168. View

15.

Fischer B, Gooch J, Goldman B, Kurdyak P, Rehm J . Non-medical prescription opioid use, prescription opioid-related harms and public health in Canada: an update 5 years later. Can J Public Health. 2014; 105(2):e146-9. PMC: 6972194. DOI: 10.17269/cjph.105.4143. View

16.

Gomes T, Mamdani M, Paterson J, Dhalla I, Juurlink D . Trends in high-dose opioid prescribing in Canada. Can Fam Physician. 2014; 60(9):826-32. PMC: 4162700. View

17.

Lalonde L, Leroux-Lapointe V, Choiniere M, Martin E, Lussier D, Berbiche D . Knowledge, attitudes and beliefs about chronic noncancer pain in primary care: a Canadian survey of physicians and pharmacists. Pain Res Manag. 2014; 19(5):241-50. PMC: 4197751. DOI: 10.1155/2014/760145. View

18.

Delcher C, Wagenaar A, Goldberger B, Cook R, Maldonado-Molina M . Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Drug Alcohol Depend. 2015; 150:63-8. DOI: 10.1016/j.drugalcdep.2015.02.010. View

19.

Murphy Y, Goldner E, Fischer B . Prescription Opioid Use, Harms and Interventions in Canada: A Review Update of New Developments and Findings since 2010. Pain Physician. 2015; 18(4):E605-14. View

20.

Rutkow L, Chang H, Daubresse M, Webster D, Stuart E, Alexander G . Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use. JAMA Intern Med. 2015; 175(10):1642-9. DOI: 10.1001/jamainternmed.2015.3931. View